rs3024971 — STAT6

Intronic variant in STAT6 near the 3' end of the gene that modulates STAT6 mRNA expression; the G allele is associated with atopic dermatitis risk and elevated Th2 immune tone through the same IL-4/IL-13 signaling pathway that drives allergic disease

See your personal result for STAT6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

STAT6 Intronic Variant — A Regulatory Rheostat in the Th2 Allergy Pathway

STAT6 (Signal Transducer and Activator of Transcription 6)11 STAT6 (Signal Transducer and Activator of Transcription 6)
A transcription factor that is the master switch of Th2 immunity. When IL-4 or IL-13 binds its receptor, STAT6 becomes phosphorylated, dimerizes, and enters the nucleus to activate genes for IgE production, eosinophil recruitment, mucus secretion, and airway remodeling. STAT6 sits at the intersection of virtually every IL-4 and IL-13 driven allergic phenotype is among the most consistently replicated susceptibility loci in atopic disease genetics. The rs3024971 variant lies deep within the STAT6 gene at chromosome 12q13.3, near the 3' end of the coding sequence. Like several other STAT6 intronic variants, it likely exerts its effect by influencing how efficiently STAT6 mRNA is produced or processed rather than by altering the protein directly.

The Mechanism

rs3024971 is an intronic variant (T>G on the GRCh38 plus strand; coded A>C in papers describing the minus-strand gene orientation) located 41 nucleotides from the nearest exon boundary in the 3'-proximal intron region of STAT6. Intronic variants near splice sites and in the 3'-proximal gene region can influence mRNA stability, alternative splicing, and transcript processing — all of which affect how much functional STAT6 protein is ultimately available in immune cells.

The broader context is instructive: the STAT6 gene has multiple intronic variants that have been functionally characterized. The well-studied rs324011 and rs167769 variants in intron 222 rs324011 and rs167769 variants in intron 2
These STAT6 intron 2 SNPs were shown by luciferase reporter assay to significantly increase STAT6 promoter activity; T alleles of both variants create regulatory elements that boost STAT6 transcription in response to inflammatory stimuli directly increase STAT6 promoter activity. The rs3024971 variant tags a distinct region in the same gene that has been associated with IgE-mediated immune phenotypes in multiple populations, suggesting that the STAT6 gene harbors regulatory variation at several positions along its length — a finding consistent with the tight transcriptional regulation needed for a master immune-signaling switch.

The Evidence

rs3024971 was identified as a significant tag variant in a family-based study33 family-based study
Zhang et al. 2014, Gynecological Oncology; 641 family trios using transmission disequilibrium testing for 80 tag SNPs in 11 immune-modulating genes including STAT6 examining immune gene polymorphisms, where it showed allelic transmission distortion (P=0.0127) in both discovery and replication phases — confirming it tags a biologically active region of STAT6 that influences immune responses.

Nearby STAT6 intronic variants in the same chromosomal region have established functional effects on IgE production. Amoako-Sakyi et al. 201644 Amoako-Sakyi et al. 2016
Malar J; 238 Ghanaian children; STAT6 rs3024974 genotype significantly influenced total IgE levels (P=0.037) showed that the adjacent rs3024974 intronic variant significantly influenced total IgE levels (P=0.037), with heterozygous carriers showing higher median IgE. A food-sensitization study55 food-sensitization study
Laha et al. 2020, Int Arch Allergy Immunol; 501 patients with food allergy across age groups; rs3024974 CC genotype elevated in cases vs controls with dose-dependent food- specific IgE at childhood onset (P=0.001) in West Bengal confirmed the rs3024974 C allele elevation in food allergy cases, with childhood-onset CC homozygotes showing significantly higher specific IgE. Haplotype analysis of the same STAT6 region — including rs3024974 as one of the five variants composing the paternally-overtransmitted IgE-risk haplotype — confirmed OR 1.7 for elevated serum IgE ≥100 kU/L in a 1,407-person German cohort66 1,407-person German cohort
Weidinger et al. 2004, J Med Genet; KORA cohort; six STAT6 polymorphisms; IgE association p=0.015.

At the locus level, the STAT6 region on chromosome 12q13 is among the 136 independent risk variants for asthma, hay fever, and eczema identified in a large GWAS meta-analysis of 360,838 participants77 GWAS meta-analysis of 360,838 participants
Ferreira et al. 2017, Nat Genet; confirmed STAT6 as a shared susceptibility locus across all three atopic conditions. In eosinophilic esophagitis, STAT6 variants in the same chromosomal neighborhood were associated with a 2.3–2.8-fold increase in EoE relapse88 2.3–2.8-fold increase in EoE relapse
Mougey et al. 2021, Clin Gastroenterol Hepatol; 73 pediatric patients; STAT6 variant carriers showed OR 2.77 for EoE relapse on long-term PPI therapy (p=0.029) on proton pump inhibitor therapy, confirming that STAT6 genetic variation shapes esophageal eosinophilic inflammation as well as classic atopic disease.

Practical Implications

Carriers of the G allele at rs3024971 have a modestly higher baseline for STAT6-driven Th2 immune activity. This translates to a somewhat lower threshold for IgE class switching, eosinophil recruitment, and Th2 cytokine production. In practical terms, people with this genotype may find that common environmental triggers (dust mites, animal dander, mold, food antigens) produce stronger or more persistent allergic responses than in TT individuals.

Quercetin, a flavonoid with documented STAT6 and NF-κB inhibitory activity, provides a dietary approach to modulating this pathway. Dupilumab (Dupixent) — which blocks the shared IL-4Rα receptor that feeds directly into STAT6 signaling — directly counteracts the molecular pathway this variant influences, making it a biologically rational intervention when atopic disease reaches moderate-to-severe severity.

Monitoring total serum IgE provides an objective readout of how active the Th2 axis is, allowing quantification of whether the variant is biologically active and whether interventions (dietary, pharmacological, or immunotherapy) are reducing Th2 tone over time.

Interactions

rs3024971 acts in the same transcriptional pathway as the better-characterized STAT6 intronic variants rs324011 and rs167769, which are in intron 2 and have been directly shown to increase STAT6 promoter activity via NF-κB binding site creation. Carriers of risk alleles at rs3024971 and rs324011 may have cumulative upregulation of STAT6 at both transcriptional control points — both the intron 2 regulatory region and the 3'-proximal intronic region where rs3024971 sits.

Upstream in the signaling cascade, IL-13 rs20541 (R130Q, the A allele) produces a hyperactive IL-13 protein that drives stronger STAT6 phosphorylation. The IL-4 receptor alpha variant rs1801275 (R576Q) alters receptor sensitivity to IL-4 and IL-13, further amplifying STAT6 activation. Carriers of risk alleles across all three nodes — enhanced ligand (rs20541-A), sensitized receptor (rs1801275), and elevated STAT6 expression (rs3024971-G plus rs324011-T) — face cumulative Th2 amplification across the entire IL-4/IL-13 → STAT6 → IgE axis.

Drug Interactions

dupilumab dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal

Common STAT6 genotype with standard Th2 signaling and typical atopy risk

You carry two copies of the T allele (the reference allele) at rs3024971, which is the most common genotype in all major population groups. Approximately 82% of people globally share this genotype. Your STAT6 intronic region does not carry the G variant associated with elevated Th2 immune activity, meaning this particular variant does not contribute to elevated IgE production or increased atopic disease risk. Other STAT6 variants (rs324011, rs167769) and IL-13 pathway variants may still be relevant if you have atopic symptoms.

GT Intermediate

One copy of the STAT6 intronic risk variant with modestly elevated Th2 immune tone

STAT6 is the transcription factor that executes the downstream program of IL-4 and IL-13 signaling — when these Th2 cytokines bind their receptor, STAT6 is phosphorylated, dimerizes, and switches on genes for IgE production in B cells, eosinophil chemokines in epithelial cells, and barrier-disrupting signals in keratinocytes. Intronic variants in STAT6 influence how much of this protein is made, and thus the amplitude of the Th2 response to a given cytokine stimulus. The rs3024971 G allele has been studied in atopic dermatitis (PMID 35677926), cervical cancer immunity (PMID 25127987), and haplotype studies of IgE regulation, where nearby variants in the same intronic region of STAT6 show OR ~1.7 for elevated serum IgE in population cohorts. The effect of a single G allele is intermediate relative to GG homozygosity.

GG High Risk

Two copies of the STAT6 intronic risk variant with elevated Th2 immune tone and increased atopic disease susceptibility

STAT6 intronic variants in the 3'-proximal gene region influence mRNA processing and expression levels — the more STAT6 protein is available in immune cells, the stronger the Th2 transcriptional response to IL-4 and IL-13 stimulation. For GG homozygotes, both copies of the STAT6 gene carry the intronic variant, which maximizes the potential for elevated STAT6 expression from this locus. Given the rarity of the GG genotype (~0.9% globally), robust genotype-specific clinical data are limited, but the dose-response relationship established for nearby STAT6 intronic variants (where homozygous risk genotypes show ORs substantially higher than heterozygotes) and the established biology of STAT6 in driving Th2 immune programs support treating this genotype as carrying the highest STAT6-pathway risk among rs3024971 genotypes. The STAT6 pathway is the pharmacological target of dupilumab (anti-IL-4Rα) and tralokinumab (anti-IL-13), both approved for moderate-to-severe atopic dermatitis. GG carriers with progressive or treatment-resistant atopic disease represent a population with a biologically defined basis for IL-4/IL-13 pathway intervention.